Skip to contentH
Hepion Pharmaceuticals, Inc.
H
HEPAHepion Pharmaceuticals, Inc. Q3 2023 · 10-Q
Revenue$0.00$0.00— vs Q3 2022 Net Income-$10.53M-$10.53MN/M vs Q3 2022 EPS Diluted-$2.74-$2.74N/M vs Q3 2022 Operating Income-$10,664,565N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Hepion Pharmaceuticals, Inc. · CIK 1583771 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$11,233,660N/M ended Sep 30, 2023 · filed Nov 20, 2023 · 51 d after period end